I dentification of heart failure pathogenesis can have important therapeutic and prognostic implications. 1 Endomyocardial biopsy (EMB), the gold standard for in vivo diagnosis of specific myocardial disorders, is often considered when the pathogenesis of heart failure cannot be determined by noninvasive testing. Because of the invasiveness of the procedure and complication risks, it has often been a challenge to identify the correct clinical setting in which to use a diagnostic EMB. [2] [3] [4] [5] [6] As a result, the indications for EMB have historically been a subject of debate.
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To address these challenges, the 2007 American Heart Association/American College of Cardiology/European Society of Cardiology (AHA/ACC/ESC) scientific statement on the role of EMB in the management of cardiovascular disease outlined 14 clinical scenarios where the diagnostic, therapeutic, and prognostic values of EMB may outweigh the procedural risks, and EMB results may meaningfully estimate prognosis or guide treatment. 7 The consensus statement was organized by clinical scenario, rather than histological diagnosis and, therefore, is intended to be useful in clinical practice when considering EMB for an individual patient with unexplained heart failure.
No randomized, controlled data exist on the use of EMB, and the AHA/ACC/ESC statement on the indications for EMB reflects this paucity of data. Many of the guideline recommendations are based on small case series and expert opinion alone. Moreover, the guidelines strongly recommend EMB in only 2 relatively uncommon clinical scenarios. This lack of evidence highlights the need for more data on the clinical use of EMB in diagnosis of unexplained heart failure. Additionally, there have been no evaluations of how an EMB changes clinical management.
The goal of this study was to provide physicians with accurate information about the likelihood that an EMB will provide useful information for a given clinical scenario. A better understanding of the potential diagnostic yield and impact on management of EMB will ultimately lead to optimized selection of candidates for EMB and better insight into the balance between risks and benefits. To examine this question, we analyzed the clinical characteristics of 851 patients who underwent EMB at the Johns Hopkins Hospital. Each patient was categorized into 1 of the 14 clinical scenarios as outlined by the AHA/ACC/ESC guidelines. We then determined whether the biopsy provided a diagnosis, changed therapy, or altered the clinical course in any significant fashion. We also examined the number and types of complications associated with EMB in this large cohort of patients.
Methods

Patient Selection
This retrospective single-center review of the pathology database, the electronic patient record, and EMB procedure reports includes 851 patients with heart failure symptoms who underwent diagnostic EMB at the Johns Hopkins Hospital between January 2000 and March 2009. The majority of the EMBs were performed using the Argon Jawz Endomyocardial Bioptome. Average number of pieces obtained per procedure was 5.6. Post-transplant patients and patients who received an EMB at the time of open heart surgery were excluded. For the majority of patients, hemodynamic parameters were measured with a right heart catheter at the time of EMB. Patient records were reviewed for demographic data and clinical course before and after EMB. The study was approved by the Institutional Review Board of the Johns Hopkins Hospital.
Pathological Findings and Diagnosis
A cardiac pathologist examined all specimens at a minimum of 4 section levels with typical stains used in evaluating native EMB. 8 The presence of and extent of inflammatory cells were generally characterized using immunohistochemical labeling for lymphocytes (CD3 or CD8) and macrophages (CD68 or MAC387). This staining was used to confirm the histological appearance of myocarditis as established by the Dallas Criteria. 9 Prussian blue and Congo red stains (or Thioflavin T) were used to identify the presence of iron and amyloid, respectively. Reflecting the historical time course of this collection, a subset of amyloid cases was typed by immunohistochemistry for kappa, lambda, and transthyretin. Mass spectrometry-based proteomic analysis of amyloid type has only been available since mid-2009. 10 Doxorubicin cardiac toxicity was established and graded by ultrastructural examination of gluteraldehyde fixed samples. Interstitial fibrosis was assessed as collagen between myocytes detected by Masson trichrome. Replacement fibrosis was characterized by the presence of discrete foci of myocyte loss associated with fibrosis and pigment-laden macrophages.
Clinical Categorization and Assessment of Impact
Each case was reviewed independently by 2 clinicians who analyzed the clinical course and EMB diagnosis, as well as the demographic and hemodynamic characteristics. Each clinician retrospectively categorized each patient into 1 of the 14 following clinical scenarios outlined in the AHA/ACC/ESC statement on EMB and determined whether the EMB result, including nonspecific or negative EMBs, meaningfully estimated prognosis or guided treatment. Each case was discussed by the study team, and any discrepancies between clinicians were reviewed in detail before a final answer was agreed on by the majority of study team. All complications associated with the EMB were recorded.
Statistical Analysis
For each clinical scenario, the frequency at which EMB provided a diagnosis or altered clinical management was calculated. Mean values and standard deviations were calculated as appropriate. We calculated the total number, type, and frequency of complications associated with EMB. The diagnostic and clinical yield of EMB for each clinical scenario was scored as high or low based on the relative average frequency at which EMB provided a diagnosis or altered clinical management.
Results
Patient Population
A total of 851 patients underwent diagnostic EMB at our medical center from 2000-2009. Table 1 lists study patient baseline characteristics with clinical and hemodynamic data. Of the 851 patients, 201 had heart failure symptoms for >1 year at the time of EMB. The remainder of the patients had heart failure symptoms for an average of 70 days.
Categorization of Biopsies
As shown in Table 2 , each patient was categorized into 1 of the 14 clinical scenarios outlined in the AHA/ACC/ESC statement. All scenarios were represented. Scenario 6, patients with heart failure associated with an unexplained restrictive cardiomyopathy, was the most common clinical scenario, comprising 33.6% (286/851) of the biopsies. Scenario 10 was the next most common scenario for EMB at 15.7% (134/851). Class I-recommended scenarios 1 and 2 comprised 16.2% (138/851) of EMBs. Biopsies for suspected allergic reaction, unexplained atrial fibrillation, unexplained ventricular arrhythmias, and cardiac tumors together comprised <3% (24/851) of the total biopsies. Table 3 details the diagnostic yield and the impact of the biopsy on the subsequent clinical care. Figure 1 in the onlineonly Data Supplement shows representative images of specific diagnoses made on EMB. For each of the 14 clinical scenarios, the number and types of diagnoses provided by EMB and the manner in which a result meaningfully affected management were determined. Thirty-nine percentage (42/109) of the biopsies for unexplained heart failure of <2 weeks duration (scenario 1) were diagnostic, a higher percentage of diagnostic biopsies than any other common scenario. As shown in Table 4 , there were 33 cases of myocarditis, including 3 cases of giant cell myocarditis (GCM). Within scenario 1, 27.5% (30/109) of the biopsies resulted in a change in management, with most clinical decisions involving the administration or withholding of immunosuppressive agents (Table 5 ). There were 84 (29.4%) diagnostic biopsies for unexplained heart failure associated with unexplained restrictive cardiomyopathy (clinical scenario 6), including 57 diagnoses of amyloidosis. Of note, there were 18 EMBs negative for amyloid Time since onset of heart failure symptoms at biopsy in patients with symptoms for <1 y, d
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No. of patients with symptoms for ≥1 y at time of biopsy 201 that also significantly changed management. EMB for unexplained restrictive cardiomyopathy also yielded other diagnoses, including 3 cases of cardiac sarcoidosis, 1 case of Fabry disease, and 1 case of hemochromatosis. There were 4 cases of amyloid among 28 patients with heart failure associated with unexplained hypertrophic cardiomyopathy (scenario 11). Three negative biopsies for scenario 11 ruled out amyloid and resulted in a change in management. There were 4 relatively uncommon clinical scenarios that had both a high diagnostic and clinical yield. Fifty percentage (12/24) of the EMBs performed in patients suspected of having anthracycline-induced cardiomyopathy (scenario 5) confirmed the diagnosis. Furthermore, negative EMB altered management of 3 additional cases of suspected anthracycline toxicity by changing prognosis, or influencing the decision to administer additional chemotherapy. On 1 occasion, an EMB that ruled out anthracycline toxicity cleared a patient for mitral valve surgery. Of the 4 cases of EMB for suspected cardiac tumors (scenario 7), 1 case was diagnostic of a diffuse large B cell lymphoma that influenced the course of therapy. Of 9 EMBs, 3 (33%) for unexplained heart failure associated with a suspected allergic reaction and eosinophilia (scenario 4) were diagnostic, including 2 cases of eosinophilic myocarditis and 1 of borderline myocarditis. In scenario 12, there were 15 cases where EMB was diagnostic. Ten percentage (6/62) of EMBs for suspected arrhythmogenic right ventricular (RV) dysplasia/cardiomyopathy (ARVD/C, scenario 12) had adipose or fibrosis supportive of the diagnosis of ARVD/C. Work by Basso et al 11 demonstrated that in ARVD/C, the RV septum was infrequently affected and, therefore, of lesser diagnostic value. The RV free wall and apex was targeted for EMB in over half of these suspected ARVD/C cases in our study as part of a clinical protocol. Of Borderline myocarditis 1
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Borderline myocarditis 14 (Continued) the 24 cases where EMB changed the clinical course, 18 cases were not diagnostic/suggestive of ARVD/C. Of these, 3 diagnoses of myocarditis and 2 diagnoses of infiltrative disease led to tailored therapy. Additionally, there were 6 decisions to withhold implantable cardiac defibrillator, and 6 cases where a negative EMB led to a workup for an alternative diagnosis.
There were several clinical scenarios for which EMB had low clinical yield. There were 234 biopsies performed for heart failure of >2 weeks duration that responded to usual care (scenarios 9 and 10). Of these, 15% (35/234) were diagnostic and only 12% (28/234) changed management. Of 26 EMBs, 3 (11.5%) for scenario 3 changed the clinical course. There were 8 patients who underwent EMB for unexplained ventricular arrhythmias (scenario 13), with only 1 EMB resulting in a change in management. There were no specific diagnoses among the 3 biopsies for unexplained atrial (Continued) Changed/removed previously diagnosed ARVD 1
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Borderline Myocarditis
Borderline myocarditis was defined using the strict Dallas Criteria of inflammatory infiltrate too sparse or myocyte damage not apparent. It is difficult to categorize borderline myocarditis as being a specific or nonspecific diagnosis because of the unclear significance of this finding. We chose to include this entity as a specific diagnosis because this finding altered clinical management in 21.6% of the subjects versus 9.6% of the biopsies considered nondiagnostic based on histopathology. Overall, 61 borderline myocarditis cases were observed, representing 7% of the overall cohort and 27.6% of the specific diagnoses rendered. Borderline myocarditis was most frequently observed in scenarios 6, 10, and 1 (Table 4 ). This diagnosis led to a change in management in 12 cases. Of these, 8 cases led to the initiation of steroids. In the remaining cases, EMB results altered management by ruling out ARVD, excluding an infiltrative process, or canceling plans for surgery.
EMB Complications
There were 16 complications in 851 biopsies for an overall complication rate of 1.9%. Of these, there were 8 major EMB-associated complications, which included 7 cases of perforation, 5 of these required pericardiocentesis. There was 1 case of ventricular fibrillation with cardiac arrest. There were 9 minor complications, including 2 cases of supraventricular tachycardia, 3 cases of transient heart block, 1 episode of bradycardia, 1 arterial puncture during sheath insertion, 1 vasovagal reaction, and 1 case of pleuritic chest pain. There were no deaths as a result of complications from the biopsy.
Discussion
EMB is often considered in unexplained heart failure when a diagnosis is likely to substantially alter clinical management or prognosis. Our study is the first to examine the diagnostic and therapeutic performance of EMB within the context of clinical scenarios outlined in the ACC/AHA/ESC guidelines on the role of EMB in the management of cardiovascular disease. We assigned 851 patients who underwent EMB at Johns Hopkins Hospital between 2000 and 2009 to 1 of 14 clinical scenarios, which serve as indicators for EMB, and examined the diagnostic and clinical value of EMB for each. Overall, we found that 25.5% of EMBs provided a diagnostic result, and 22.6% of EMBs changed clinical course.
EMB for Acute Onset Heart Failure
The timely identification and treatment of GCM is the main reason to consider EMB in acute onset heart failure that involves hemodynamic instability or does not respond to usual care (clinical scenarios 1 and 2). 7 The ability to distinguish GCM from other forms of myocarditis has important clinical implications in terms of prognosis and response to immunosuppressive agents. 12 Fulminant heart failure caused by lymphocytic myocarditis may have a better prognosis than GCM or eosinophilic myocarditis. 13 Improved outcomes have been observed in GCM and eosinophilic myocarditis with the use of combinations of immunosuppressive agents.
14 In this study, EMB for acute onset unexplained heart failure, which is hemodynamically unstable or does not respond to usual care, has both high diagnostic and clinical yield, and our results suggest that EMB is clinically useful and should be performed in patients with these clinical scenarios. We did not routinely obtain viral genomes in our study. Emerging molecular biology techniques may eventually lead to new classifications of myocarditis and ultimately expand indications for EMB. For example, in the recent TIMIC (Tailed Immunosuppression in Inflammatory Cardiomyopathy) trial, Frustaci et al 15 used a broader definition of myocarditis based on the expression of CD3/CD45 and adhesion molecules to identify a population of patients with virus-negative inflammatory-dilated cardiomyopathy who might benefit from immunosuppressive treatment.
EMB for Suspected Infiltrative Disease
EMB, particularly coupled with mass spectrometry-based proteomic typing of amyloid, is useful in the management of cardiac amyloidosis, given the prognostic and therapeutic importance of establishing the specific type of amyloid. 10, 16, 17 Unexplained restrictive cardiomyopathy (clinical scenario 6) was the most common clinical scenario encountered in our study, accounting for approximately one third of the EMBs. Other methods of detecting amyloid are historically less reliable. For example, in cases of TTR amyloidosis, the fat pad aspirate is negative when cardiac biopsy is positive in ≈50% of cases. Based on our findings of a high diagnostic and clinical yield of EMB in this setting, it is reasonable to perform EMB in the setting of suspected infiltrative disease that presents as either a restrictive or unexplained hypertrophic cardiomyopathy (clinical scenario 11).
EMB in Rare Clinical Scenarios
There were several relatively uncommon clinical scenarios comprising <12% of all cases in the study, where EMB was particularly useful. There is a high yield of EMB in cases of suspected hypersensitivity myocarditis (clinical scenario 4). EMB was also useful in cases of suspected anthracycline cardiomyopathy (clinical scenario 5) where there was uncertainty about cardiac dysfunction pathogenesis with a history of anthracycline use, or when treatment with additional potentially cardiotoxic chemotherapeutic agents is being considered. EMB for suspected cardiac tumors (clinical scenario 7) also demonstrated a high diagnostic yield. Finally, although we did not perform morphometric analysis, the findings suggest that the use of EMB might be helpful in the diagnosis of ARVD/C (clinical scenario 12). This supports the recent ARVC/D task force criteria, which defined one of the major criteria as residual myocytes <60% by morphometric analysis with fibrous replacement in >1 sample, with or without fatty replacement of tissue.
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The decision to perform EMB in chronic heart failure should be made either based on the clinical suspicion for infiltrative disease, specifically in the presence of unexplained restrictive disease or hypertrophic cardiomyopathy, or in the setting of one of the rare clinical scenarios described above. EMB for unexplained heart failure of >2 weeks duration, which responds to usual care, or heart failure >3 months duration, regardless of the presence of new ventricular arrhythmias or heart block, (scenarios 3, 9, and 10) may be considered, but has a low diagnostic and clinical yield.
EMB was not particularly helpful in the diagnosis and management of sarcoidosis (scenario 3) or lymphocytic myocarditis. Patients with cardiac sarcoid often present with chronic heart failure and have ventricular tachycardia and heart block. However, patients often have a heterogeneous distribution of noncaseating granulomas in the myocardium. The histological yield in sarcoidosis biopsy is thought to be only ≈19%. 20 In our study, there were few patients that fit scenario 3, and the diagnostic yield and the clinical impact of biopsies for this indication were both relatively low. In the future, novel techniques, such as the use of endocardial voltage mapping catheters, may increase the diagnostic yield of EMB by identifying regions of inflammation in the setting of suspected sarcoidosis. Clinical scenario 9 is intended to capture cases of lymphocytic myocarditis that do not have a fulminant course. Our findings are consistent with previous studies that found the incidence of lymphocytic myocarditis in patients with new-onset unexplained heart failure of this duration is quite variable. 21 The majority of patients with unexplained heart failure of this duration respond to standard heart failure therapy, and a diagnosis of myocarditis within this time frame rarely effects prognosis or alters treatment in a meaningful fashion. 12, [22] [23] [24] 
EMB for Atrial or Ventricular Arrhythmias
In our single-center experience, unexplained ventricular arrhythmias or atrial fibrillation (clinical scenarios 13 and 14) were uncommon indications for EMB. The 11 biopsies performed for these specific indications during the 10-year study period had a low clinical yield. Our findings are consistent with the recommendation that EMB should not be considered in these clinical scenarios. However, because of the small sample size, no strong recommendations can be made in this group.
Limitations
In our single-center experience, only EMB of the RV was performed in all patients. EMB of the left ventricle or both ventricles may affect diagnostic yield and complication rates. Yilmaz et al 5 have shown that for unexplained heart failure, there may be increased efficacy when both a left ventricular biopsy and an RV biopsy are performed. In their study of the 254 patients with EMB-proven myocarditis, 80.3% had biventricular involvement, whereas 12.6% had a positive left ventricular EMB alone. They also found that the rate of major complications (perforations and strokes) was similar between left ventricular and RV biopsies and found fewer minor complications with left ventricular than with RV biopsies. Their reported rates of major complications of 1% and minor complications between 2.24% (left ventricle) and 5.1% (RV) are comparable with the overall EMB complication rate of 1.9% rate observed in our study, and are consistent with historically reported rates based on other single-center experiences.
There are several limitations to this study. We examined EMB retrospectively at a single tertiary medical center with significant technical expertise in performing the procedure and interpreting EMB specimens. Therefore, the case mix and frequency of specific diseases encountered in our study and the use of EMB for a given scenario may differ compared with a small community hospital. In our study, fluoroscopy was used to guide EMB of the RV. EMB by echocardiographic guidance or may affect complication rates as well as diagnostic yield. Additionally, during the 10-year study period, MRI imaging emerged as an important tool in the diagnosis of patients with unexplained heart failure. We did not collect any MRI data in this cohort, and it is possible that some patients might not have undergone biopsy if a diagnosis was determined by MRI. Yoshida et al 25 recently reported the results of a group of patients who had both a cardiac MRI and an EMB. They found that MRI was superior for diagnosing cardiac sarcoid (75% versus 25%) and ARVC (100% versus 0%), but for myocarditis EMB was superior using a gold standard of both diagnostic techniques plus all available clinical information. 25 This study was limited by small numbers of patients with the various pathogeneses, and future studies should examine the diagnostic and clinical use of MRI compared with EMB in patients who underwent both procedures. Also, we rely solely on review of the medical record to determine both the rationale for EMB in each case and the effect of EMB on the subsequent clinical course. The medical record may not capture all of the clinical considerations, conversations, and factors that influenced medical decision making in these often complex and critically ill patients. Although we used our best judgment, it is not possible to know with absolute certainty whether EMB led to a change in therapy for each individual case. Additionally, we did not account for any variation in case mix, diagnosis, or complication rates, or clinical impact during the 10-year study period. Unexplained cardiomyopathy in children accounted for <4% of the EMB in our study, making it challenging to assess the diagnostic and clinical yields of EMB for a similar range of clinical scenarios as encountered in the adult population.
Conclusions
This study evaluates the AHA/ACC/ESC scientific statement on the role of EMB of cardiovascular disease management in the context of a large tertiary care referral center and further defines acceptable approaches to EMB use. Overall, our findings support the AHA/ACC/ESC guidelines and reflect what happens in true clinical practice. In acute onset unexplained cardiomyopathy that does not respond to usual care, EMB is valuable in diagnosis and management. Furthermore, we demonstrate a clear role of EMB in suspected infiltrative disease that presents either as unexplained hypertrophic cardiomyopathy or as restrictive disease. It is also reasonable to consider EMB in the management of less common clinical scenarios, such as suspected hypersensitivity myocarditis, anthracycline cardiomyopathy, cardiac tumors, and in suspected ARVD/C. However, there is low use of EMB in chronic symptomatic heart failure that does not fall into one of the above categories or cases of heart failure that respond to usual care.
